XOMA Royalty doubled its portfolio to over 120 royalty assets through five strategic transactions in 2024, strengthening its position as a biotech royalty aggregator.
Long-term seralutinib treatment demonstrated continued improvement in pulmonary vascular resistance through 72 weeks in PAH patients, with responders showing a median 32% reduction.
DelveInsight's latest report reveals over 55 companies actively developing 55+ pipeline drugs for Pulmonary Arterial Hypertension treatment, indicating robust research activity in this therapeutic area.
Gossamer Bio will showcase multiple analyses of seralutinib from the TORREY Phase 2 open-label extension study at the Pulmonary Vascular Research Institute 2025 Annual Congress.